Bausch Health's Thermage technology surpasses 5 million treatments

Bausch Health Companies Inc. (BHC) reported a robust Q2 2025, with earnings per share of $0.40 significantly surpassing analyst forecasts of $0.04 and revenue of $2.53 billion slightly exceeding expectations. This strong financial performance is complemented by its Thermage aesthetic technology reaching over 5 million treatments worldwide and the expanded availability of its CABTREO acne treatment in Canadian public drug plans. These operational successes, coupled with a 7.1% year-over-year revenue increase and an InvestingPro assessment labeling the stock as "undervalued," underscore Bausch Health's solid growth trajectory and market penetration efforts.

Analysis

Bausch Health Companies (BHC) delivered a robust second quarter for 2025, highlighted by an exceptional earnings per share of $0.40, which represents a 900% positive surprise against analyst forecasts of $0.04. This bottom-line outperformance was complemented by revenue of $2.53 billion, slightly exceeding expectations and marking a 7.1% year-over-year increase. The strong financial results are supported by tangible operational momentum, including a key milestone for its Thermage technology, which has now surpassed 5 million treatments globally, indicating strong product adoption in the aesthetics market. Concurrently, the company is actively expanding market access for its pharmaceutical products, with its acne treatment, CABTREO, now available under public drug plans in Quebec and Saskatchewan. The company's fundamental profile appears solid, characterized by impressive 70% gross margins and an external 'InvestingPro' analysis rating its financial health as "GREAT" and its stock as "undervalued," suggesting current market valuation may not fully reflect these positive developments.

Key Decisions for Investors

• Given the significant earnings beat, solid revenue growth, and an external assessment suggesting the stock is undervalued, investors may consider initiating or increasing a long position in BHC.
• It is critical to monitor subsequent quarters to determine if the substantial Q2 profitability is sustainable, as this will be key to validating a long-term re-rating of the stock.
• Investors should closely track the performance of the Solta Medical division and new product rollouts like CABTREO, as these appear to be primary drivers of Bausch Health's growth and market penetration strategy.